rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    HURA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
      Nov 13Yahoo FinanceHURA
      TuHURA Biosciences draws $1.5 million from existing revolving credit facility
      Nov 6Investing.comHURA
      TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
      Oct 26Yahoo FinanceHURA
      TuHURA reports tumor responses in 3-patient cancer trial
      Oct 26Investing.comHURA
      TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
      Oct 26Yahoo FinanceHURA
      TuHURA receives patent expanding TBS-2025 antibody coverage
      Oct 13Investing.comHURA
      TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
      Oct 13Yahoo FinanceHURA
      TuHURA Biosciences receives U.S. patent for DOR technology
      Oct 5Investing.comHURA
      TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
      Oct 5Yahoo FinanceHURA
      Citizens reiterates TuHURA Biosciences stock rating on AML therapy progress
      Sep 23Investing.comHURA
      TuHURA receives FDA clearance for leukemia drug trial
      Sep 14Investing.comHURA
      TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

      TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New Drug (IND) application for its TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cancers.

      Sep 14Yahoo FinanceHURA
      TuHURA Biosciences Says FDA Clears Phase 1b Trial of TBS-2025 in Acute Myeloid Leukemia

      TuHURA Biosciences (HURA) said Monday that the US Food and Drug Administration has cleared its inves

      Sep 14Yahoo FinanceHURA
      TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY.

      Sep 8Yahoo FinanceHURA
      HURA: Milestone Progression Over Next 12 Months

      By John Vandermosten, CFA NASDAQ: HURA READ THE FULL HURA RESEARCH REPORT Operational and Financial Results On August 14 th , 2026, TuHURA Biosciences, Inc. (NASDAQ: HURA) reported 2Q:26 financial and operational results and filed its Form 10-Q with the SEC. There have been several updates since the previous update in May, most notably the filing of the Investigational New Drug (IND) application

      Aug 26Yahoo FinanceHURA

      This is the newest page. Registered accounts read further back.